THELMA Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,389.05 million compared to KRW 1,658.09 million a year ago. Net loss was KRW 539.31 million compared to KRW 983.3 million a year ago. Basic loss per share from continuing operations was KRW 9 compared to KRW 40 a year ago. Diluted loss per share from continuing operations was KRW 9 compared to KRW 40 a year ago. Basic loss per share was KRW 9 compared to KRW 40 a year ago.
For the nine months, sales was KRW 4,547.9 million compared to KRW 5,891.74 million a year ago. Net loss was KRW 2,838.3 million compared to KRW 3,734.41 million a year ago. Basic loss per share from continuing operations was KRW 50 compared to KRW 152 a year ago. Diluted loss per share from continuing operations was KRW 50 compared to KRW 152 a year ago. Basic loss per share was KRW 50 compared to KRW 152 a year ago.